SPBC19C7.01 Antibody

What is SPBC19C7.01 and why is it studied in research?

SPBC19C7.01 (also referenced as SPBC32F12.13c) is an uncharacterized protein in Schizosaccharomyces pombe (fission yeast). The protein remains largely unstudied but is of interest to researchers investigating S. pombe cellular processes. Antibodies against this protein serve as tools for protein detection, localization studies, and functional characterization experiments. The protein's uncharacterized nature makes it valuable for researchers exploring novel aspects of fission yeast biology, potentially revealing new insights into conserved eukaryotic cellular mechanisms.

What applications are appropriate for SPBC19C7.01 antibody in yeast research?

SPBC19C7.01 antibody can be employed in multiple research techniques including Western blotting, immunoprecipitation, chromatin immunoprecipitation, immunofluorescence microscopy, and flow cytometry. For Western blotting, researchers typically use dilutions between 1:500-1:2000 depending on antibody sensitivity and protein abundance. Immunoprecipitation protocols generally require optimization with varying antibody concentrations (2-5 μg per sample) to achieve specific pull-down of the target protein. Immunofluorescence applications may require permeabilization optimization specific to yeast cell walls, often using enzymatic digestion with zymolyase followed by detergent treatment before antibody incubation.

How should researchers validate SPBC19C7.01 antibody specificity?

Validation of antibody specificity for uncharacterized proteins requires multiple approaches. First, researchers should perform Western blot analysis comparing wild-type strains with SPBC19C7.01 deletion mutants or strains with epitope-tagged versions of the protein. Second, peptide competition assays can verify binding specificity by pre-incubating the antibody with excess synthetic peptide corresponding to the immunogen. Third, orthogonal detection methods using differently-raised antibodies against the same target or mass spectrometry analysis of immunoprecipitated material can provide additional validation. For uncharacterized proteins like SPBC19C7.01, comprehensive validation becomes especially critical to establish research reliability.

What buffer conditions are optimal for SPBC19C7.01 antibody storage and usage?

The SPBC19C7.01 antibody is supplied in liquid form with a preservative (0.03% Proclin 300) in a buffer composed of 50% glycerol and 0.01M phosphate-buffered saline (PBS) at pH 7.4. For long-term storage, the antibody should be kept at -20°C, avoiding repeated freeze-thaw cycles by preparing working aliquots. For experimental applications, dilutions should be prepared in buffers appropriate to the specific technique, typically PBS with 1-5% BSA or non-fat dry milk for blocking non-specific interactions. When working with yeast samples, researchers should consider adding protease inhibitors to prevent degradation of the target protein during extraction and processing.

How can researchers optimize SPBC19C7.01 antibody for chromatin immunoprecipitation in S. pombe studies?

Chromatin immunoprecipitation (ChIP) with SPBC19C7.01 antibody requires specialized optimization for S. pombe. Researchers should implement a two-step crosslinking protocol using 2 mM disuccinimidyl glutarate (DSG) for 45 minutes followed by 1% formaldehyde for 20 minutes to capture both direct and indirect DNA-protein interactions. Cell wall digestion should be carefully optimized using zymolyase (1 mg/ml) at 30°C for 15-30 minutes. Sonication conditions must be empirically determined to achieve chromatin fragments of 200-500 bp, typically requiring 10-15 cycles (30 seconds on/30 seconds off) at medium-high power. For immunoprecipitation, 4-5 μg of antibody per sample with overnight incubation at 4°C yields optimal results. Including appropriate controls (IgG negative control, histone H3 positive control) is essential for result interpretation.

What approaches can resolve discrepancies between localization patterns observed with SPBC19C7.01 antibody versus tagged protein constructs?

When discrepancies arise between antibody-based detection and tagged protein localization, researchers should implement a systematic troubleshooting approach. First, verify tag interference by testing both N- and C-terminal tags using different linker lengths to minimize functional disruption. Second, compare antibody detection in fixed versus live cells to assess fixation artifacts. Third, use super-resolution microscopy techniques (STED, PALM, or STORM) with both approaches to resolve subcellular localization at higher precision. Fourth, perform functional complementation assays to determine whether tagged constructs retain native functionality. Fifth, conduct fractionation studies followed by Western blot analysis using both detection methods to biochemically validate localization patterns. Integration of these approaches provides robust resolution of discrepancies.

What strategies can overcome epitope masking when SPBC19C7.01 forms protein complexes?

Epitope masking occurs when protein-protein interactions obscure antibody recognition sites. To overcome this challenge with SPBC19C7.01 antibody, researchers can implement several strategies. First, modify extraction conditions by testing different detergents (NP-40, Triton X-100, CHAPS) at varying concentrations (0.1-1%) to disrupt weaker interactions while preserving the epitope structure. Second, implement partial denaturation protocols using low concentrations of SDS (0.01-0.05%) or urea (1-2M) in extraction buffers. Third, test multiple antibodies raised against different regions of SPBC19C7.01 if available. Fourth, apply cross-linking mass spectrometry (XL-MS) to identify interaction interfaces and select antibodies targeting exposed regions. Fifth, use proximity labeling methods (BioID or APEX) as alternative approaches to identify interaction partners without relying directly on antibody accessibility.

How can researchers quantitatively assess SPBC19C7.01 protein levels across different growth conditions?

Quantitative assessment of SPBC19C7.01 across varying conditions requires rigorous methodological approaches. Researchers should implement absolute quantification via selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) mass spectrometry using isotope-labeled peptide standards derived from SPBC19C7.01. For antibody-based quantification, establish standard curves using recombinant SPBC19C7.01 protein at known concentrations. Implement multiplex Western blotting with simultaneous detection of SPBC19C7.01 and invariant loading controls. For live-cell analysis, CRISPR knock-in of fluorescent tags at the endogenous locus followed by fluorescence correlation spectroscopy (FCS) provides single-molecule quantification capabilities. Data analysis should incorporate normalization to cell number, total protein content, and appropriate reference genes to account for experimental variations.

What protein extraction protocols are most effective for detecting SPBC19C7.01 in S. pombe?

Effective protein extraction from S. pombe for SPBC19C7.01 detection requires specialized approaches due to the rigid cell wall. The recommended protocol involves harvesting cells at mid-log phase (OD600 0.5-0.8) followed by washing in ice-cold stop buffer (150 mM NaCl, 50 mM NaF, 10 mM EDTA, 1 mM NaN3, pH 8.0). Cell wall digestion should be performed using zymolyase-100T (1 mg/ml) in 1.2 M sorbitol buffer for 30 minutes at 30°C. After osmotic lysis in extraction buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate) supplemented with protease inhibitor cocktail, mechanical disruption via bead-beating (5 cycles of 30 seconds with 30-second cooling intervals) ensures complete extraction. Centrifugation at 16,000 × g for 20 minutes removes cellular debris, yielding a protein extract suitable for immunoblotting or immunoprecipitation applications.

What experimental design best demonstrates SPBC19C7.01 function in genetic interaction studies?

A comprehensive experimental design for genetic interaction studies with SPBC19C7.01 should include multiple approaches. First, construct a SPBC19C7.01 deletion strain using PCR-based targeted gene replacement with selectable markers. Second, perform synthetic genetic array (SGA) analysis by crossing this deletion with a genome-wide deletion library to identify negative and positive genetic interactions. Third, implement targeted double mutant analysis with candidate interactors identified from SGA screens using tetrad dissection and growth rate analysis. Fourth, conduct suppressor screens by introducing random mutations into SPBC19C7.01 deletion backgrounds and selecting for phenotype reversal. Fifth, perform domain-specific mutations based on bioinformatic predictions to assess structure-function relationships. Data analysis should incorporate growth curve measurements, microscopic phenotyping, and stress response characterization to comprehensively evaluate genetic interactions.

How can researchers integrate antibody-based detection with proteomics approaches for studying SPBC19C7.01?

Integration of antibody-based detection with proteomics requires a multi-faceted approach. For comprehensive analysis, researchers should:

This integrated approach provides both qualitative interaction data and quantitative abundance measurements across experimental conditions.

What controls and normalization methods are essential when using SPBC19C7.01 antibody in comparative studies?

Robust comparative studies using SPBC19C7.01 antibody require comprehensive controls and normalization strategies. Essential negative controls include secondary antibody-only samples, isotype-matched control antibodies, and analyses in SPBC19C7.01 deletion strains. Positive controls should incorporate epitope-tagged SPBC19C7.01 strains detected with both anti-tag antibodies and SPBC19C7.01-specific antibodies. For quantitative Western blots, normalization should utilize multiple housekeeping proteins (e.g., GAPDH, tubulin, actin) and total protein staining methods (Ponceau S, SYPRO Ruby). When performing immunofluorescence, researchers should include Z-stack acquisitions to account for three-dimensional distribution variations and normalize signal intensity to cell volume. Statistical analysis should incorporate biological replicates (minimum n=3) from independent experiments rather than technical replicates to account for biological variability.

How should researchers address weak or inconsistent signals when detecting SPBC19C7.01?

When encountering weak or inconsistent signals with SPBC19C7.01 antibody, researchers should implement a systematic troubleshooting approach. First, optimize protein extraction by testing multiple lysis buffers with varying detergent compositions (RIPA, NP-40, Triton X-100) and concentrations to improve protein solubilization. Second, enhance epitope accessibility through heat-mediated or citrate buffer antigen retrieval methods. Third, increase antibody binding efficiency by extending primary antibody incubation time (overnight at 4°C) and optimizing antibody concentration through titration experiments. Fourth, amplify detection signal using high-sensitivity chemiluminescent substrates or implement tyramide signal amplification for immunofluorescence applications. Fifth, reduce background by optimizing blocking conditions with different agents (BSA, casein, normal serum) at varying concentrations. Systematic optimization of these parameters typically resolves signal detection issues.

What strategies can address cross-reactivity issues with SPBC19C7.01 antibody in multi-protein detection experiments?

Cross-reactivity challenges require targeted resolution strategies. First, researchers should perform extensive validation using SPBC19C7.01 deletion strains as negative controls and epitope-tagged strains as positive controls. Second, implement antibody pre-adsorption against total protein lysates from deletion strains to remove cross-reactive antibody populations. Third, use sequential rather than simultaneous multiplex detection to eliminate potential cross-reactivity between detection systems. Fourth, apply spectral unmixing algorithms when using fluorescence-based detection to mathematically resolve overlapping signals. Fifth, consider using alternative detection methods like proximity ligation assay (PLA) which requires two independent antibody binding events, thereby reducing false positives from single antibody cross-reactivity. These approaches collectively minimize cross-reactivity interference in multi-protein detection experiments.